Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P859 | ISIN: US03589W1027 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
2,600 US-Dollar
+1,96 % +0,050
1-Jahres-Chart
ANNEXON INC Chart 1 Jahr
5-Tage-Chart
ANNEXON INC 5-Tage-Chart

Aktuelle News zur ANNEXON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.05.Annexon berichtet über vielversprechende Ergebnisse bei Guillain-Barré-Behandlung5
ANNEXON Aktie jetzt für 0€ handeln
19.05.Annexon reports promising Guillain-Barré treatment results1
19.05.Annexon Biosciences: Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting1
16.05.Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)120BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...
► Artikel lesen
13.05.Cantor Fitzgerald maintains Overweight on Annexon stock11
12.05.Annexon, Inc. - 10-Q, Quarterly Report2
12.05.Annexon Biosciences GAAP EPS of -$0.37 misses by $0.072
12.05.Annexon Biosciences: Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones1.693FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study...
► Artikel lesen
09.05.Annexon Biosciences: Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting3
16.04.Annexon Biosciences: Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)123BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...
► Artikel lesen
10.04.Why Annexon Inc. (ANNX) Went Down On Thursday?8
09.04.Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder3
09.04.Annexon rolls out Guillain-Barré awareness campaign for HCPs amid promising results for targeted therapy6
08.04.Annexon Biosciences: Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting233Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education...
► Artikel lesen
04.04.Annexon Biosciences: Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting4
17.03.Annexon Biosciences: Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)186BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating...
► Artikel lesen
03.03.Annexon, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Annexon, Inc. - 10-K, Annual Report16
03.03.Annexon Biosciences GAAP EPS of -$0.333
03.03.Annexon, Inc. Loss At -$48.59 Mln In Q420
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1